Advertisement

Cancer Immunology, Immunotherapy

, Volume 60, Issue 3, pp 443–450 | Cite as

CIMT 2010: Report on the eighth annual meeting of the association for cancer immunotherapy, May 26–28, 2010, Mainz, Germany

  • Satwinder Kaur Singh
  • Karoline Laske
  • Cécile Gouttefangeas
  • Cedrik M. Britten
  • Marij J. P. Welters
Meeting Report

In 2010, the first therapeutic vaccine against cancer received approval of the Food and Drug Administration (FDA) in USA. In addition, several reports from randomized phase III trials showing improved survival in cancer patients receiving immunotherapy raised great hopes for the field of cancer immunotherapy. These recent reports formed the central topic in many discussions among participants of the Association for Cancer Immunotherapy Meeting (CIMT) 2010, who had been longing for major tangible breakthroughs in clinical immunotherapy development for several years. With the number of attendants gradually increasing to above 450 international participants, the series of annual CIMT meetings has definitively placed itself as one of the top European meetings focussing on immunology and cancer. This is also reflected by the increasing number of industrial exhibitors, three well-visited satellite workshops and over 120 submitted abstracts from which 25 were selected for oral presentations,...

Keywords

Ipilimumab Granulocyte Macrophage Colony Stimulate Factor Prostatic Acid Phosphatase Renal Cell Carcinoma Epitope Spreading 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Satwinder Kaur Singh
    • 1
  • Karoline Laske
    • 2
  • Cécile Gouttefangeas
    • 2
  • Cedrik M. Britten
    • 3
  • Marij J. P. Welters
    • 1
  1. 1.Department of Clinical OncologyLeiden University Medical CentreLeidenThe Netherlands
  2. 2.Department of Immunology, Institute for Cell BiologyUniversity of TübingenTübingenGermany
  3. 3.Division of Experimental and Translational Oncology, Department of Internal Medicine IIIJohannes Gutenberg-UniversityMainzGermany

Personalised recommendations